A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection (cASPerCF)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04966234 |
Recruitment Status : Unknown
Verified March 2021 by Bambino Gesù Hospital and Research Institute.
Recruitment status was: Recruiting
First Posted : July 19, 2021
Last Update Posted : July 19, 2021
|
Sponsor:
Bambino Gesù Hospital and Research Institute
Collaborators:
University of Exeter
Radboud University Medical Center
Consorzio per Valutazioni Biologiche e Farmacologiche
Information provided by (Responsible Party):
Bambino Gesù Hospital and Research Institute
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | April 2023 |
Estimated Study Completion Date : | November 2023 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
December 22, 2022 | October 19, 2023 |
Publications: